A comprehensive strategy of network pharmacology and molecular docking reveals Danshenol a as a main active component of Huoluoxiaolingdan in ameliorating acute myocardial infarction
This study elucidates XLD's pleiotropic mechanisms in AMI management through network pharmacology approaches and identifies DA as a main active component XLD in alleviating AMI. These findings provide novel insights into XLD's cardioprotective pharmacology.
Authors
- Lei Zhang (ORCID: https://orcid.org/0000-0002-0580-0889)
- Guifang Liu (ORCID: https://orcid.org/0000-0001-7660-9902)
- Tao Geng (ORCID: https://orcid.org/0000-0001-9854-4097)
- Die Lin
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Xiyuan Hospital (CN)
- Guang’anmen Hospital (CN)
Publication Details
- Journal
- International Immunopharmacology
- Published
- 2025-12-11
- DOI
- https://doi.org/10.1016/j.intimp.2025.115955
- Primary Topic
- Traditional Chinese Medicine Analysis
- Type
- article
- Field-Weighted Citation Impact
- 0.00